[go: up one dir, main page]

GB201619949D0 - nOMV-antigen conjugated compounds and use thereof - Google Patents

nOMV-antigen conjugated compounds and use thereof

Info

Publication number
GB201619949D0
GB201619949D0 GBGB1619949.9A GB201619949A GB201619949D0 GB 201619949 D0 GB201619949 D0 GB 201619949D0 GB 201619949 A GB201619949 A GB 201619949A GB 201619949 D0 GB201619949 D0 GB 201619949D0
Authority
GB
United Kingdom
Prior art keywords
nomv
conjugated compounds
antigen conjugated
antigen
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1619949.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to GBGB1619949.9A priority Critical patent/GB201619949D0/en
Publication of GB201619949D0 publication Critical patent/GB201619949D0/en
Priority to HRP20210121TT priority patent/HRP20210121T1/hr
Priority to HUE17816489A priority patent/HUE052751T2/hu
Priority to CA3044572A priority patent/CA3044572A1/en
Priority to JP2019527842A priority patent/JP7165468B2/ja
Priority to ES17816489T priority patent/ES2847947T3/es
Priority to DK17816489.3T priority patent/DK3544637T3/da
Priority to US16/462,630 priority patent/US20230137914A1/en
Priority to PCT/EP2017/080151 priority patent/WO2018096013A1/en
Priority to MX2019006105A priority patent/MX2019006105A/es
Priority to PL17816489T priority patent/PL3544637T3/pl
Priority to LTEP17816489.3T priority patent/LT3544637T/lt
Priority to CN201780084566.9A priority patent/CN110248681A/zh
Priority to BR112019010625A priority patent/BR112019010625A2/pt
Priority to SI201730587T priority patent/SI3544637T1/sl
Priority to EP17816489.3A priority patent/EP3544637B1/en
Priority to BE2017/5856A priority patent/BE1025443B1/fr
Priority to PT178164893T priority patent/PT3544637T/pt
Priority to EP20206493.7A priority patent/EP3799883A1/en
Priority to ARP170103286A priority patent/AR110236A1/es
Priority to CY20211100044T priority patent/CY1123814T1/el
Priority to JP2022168070A priority patent/JP2023011688A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1619949.9A 2016-11-25 2016-11-25 nOMV-antigen conjugated compounds and use thereof Ceased GB201619949D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
GBGB1619949.9A GB201619949D0 (en) 2016-11-25 2016-11-25 nOMV-antigen conjugated compounds and use thereof
EP20206493.7A EP3799883A1 (en) 2016-11-25 2017-11-23 Nomv-antigen conjugated compounds and use thereof
PL17816489T PL3544637T3 (pl) 2016-11-25 2017-11-23 Konjugaty natywnego omv-antygenu i ich zastosowanie
CN201780084566.9A CN110248681A (zh) 2016-11-25 2017-11-23 nOMV-抗原缀合物及其用途
CA3044572A CA3044572A1 (en) 2016-11-25 2017-11-23 Nomv-antigen conjugates and use thereof
JP2019527842A JP7165468B2 (ja) 2016-11-25 2017-11-23 ｎＯＭＶ－抗原コンジュゲート及びその使用
ES17816489T ES2847947T3 (es) 2016-11-25 2017-11-23 Conjugados de VMEn-antígeno nativas y uso de los mismos
DK17816489.3T DK3544637T3 (da) 2016-11-25 2017-11-23 Native omv-antigenkonjugater og anvendelse deraf
US16/462,630 US20230137914A1 (en) 2016-11-25 2017-11-23 nOMV-ANTIGEN CONJUGATED COMPOUNDS AND USE THEREOF
PCT/EP2017/080151 WO2018096013A1 (en) 2016-11-25 2017-11-23 nOMV-ANTIGEN CONJUGATES AND USE THEREOF
MX2019006105A MX2019006105A (es) 2016-11-25 2017-11-23 Conjugados de vmen-antigeno y uso de los mismos.
HRP20210121TT HRP20210121T1 (hr) 2016-11-25 2017-11-23 Konjugati nativnog omv-antigena i njihova upotreba
LTEP17816489.3T LT3544637T (lt) 2016-11-25 2017-11-23 Natyvių omv ir antigeno konjugatai bei jų naudojimo būdas
HUE17816489A HUE052751T2 (hu) 2016-11-25 2017-11-23 Natív OMV-antigén konjugátumok és alkalmazásuk
BR112019010625A BR112019010625A2 (pt) 2016-11-25 2017-11-23 conjugado imunogênico, processo para preparar o conjugado imunogênico, nomv-ligante intermediário, usos do mesmo e de nomv, composição imunogênica, e, vacina.
SI201730587T SI3544637T1 (sl) 2016-11-25 2017-11-23 Nativni OMV-antigen konjugati in njihova uporaba
EP17816489.3A EP3544637B1 (en) 2016-11-25 2017-11-23 Native omv-antigen conjugates and use thereof
BE2017/5856A BE1025443B1 (fr) 2016-11-25 2017-11-23 CONJUGUES nOMV-ANTIGENE ET LEUR UTILISATION
PT178164893T PT3544637T (pt) 2016-11-25 2017-11-23 Conjugados omv-antigénio nativos e sua utilização
ARP170103286A AR110236A1 (es) 2016-11-25 2017-11-24 Conjugados de vmen-antígeno y uso de los mismos
CY20211100044T CY1123814T1 (el) 2016-11-25 2021-01-20 ΣΥΖΕΥΓΜΑΤΑ nOMV-ΑΝΤΙΓΟΝΟΥ ΚΑΙ ΧΡΗΣΗ ΑΥΤΩΝ
JP2022168070A JP2023011688A (ja) 2016-11-25 2022-10-20 ｎＯＭＶ－抗原コンジュゲート及びその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1619949.9A GB201619949D0 (en) 2016-11-25 2016-11-25 nOMV-antigen conjugated compounds and use thereof

Publications (1)

Publication Number Publication Date
GB201619949D0 true GB201619949D0 (en) 2017-01-11

Family

ID=58073117

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1619949.9A Ceased GB201619949D0 (en) 2016-11-25 2016-11-25 nOMV-antigen conjugated compounds and use thereof

Country Status (2)

Country Link
AR (1) AR110236A1 (es)
GB (1) GB201619949D0 (es)

Also Published As

Publication number Publication date
AR110236A1 (es) 2019-03-06

Similar Documents

Publication Publication Date Title
IL273236A (en) Pyrazolopyrimidine compounds and their uses
IL255577B (en) Binding materials - tigit and their uses
IL253433A0 (en) Binders - tnfrsf and their uses
IL264813B (en) 2-oxo-imidazopyridines and their use
GB201714745D0 (en) New compounds and uses
IL292488B1 (en) Pyridineamine-pyridone and pyrimidineamine-pyridone compounds
GB201714734D0 (en) New compounds and uses
GB201714740D0 (en) New compounds and uses
PT3544637T (pt) Conjugados omv-antigénio nativos e sua utilização
GB201616439D0 (en) Compounds and uses
SG10201602152UA (en) Improved spreader and use thereof
IL269836B (en) Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
IL292482B1 (en) Azaindolylpyridone and diazaindolylpyridone compounds
GB201714736D0 (en) New compounds and uses
GB201712110D0 (en) New compounds and uses
GB201700404D0 (en) Compounds and composistions
GB201614224D0 (en) Compounds and uses thereof
IL269843B (en) Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use
GB201619949D0 (en) nOMV-antigen conjugated compounds and use thereof
IL265617B (en) 1-phenylpropanone compounds and their use
GB201720092D0 (en) New Compounds and uses
GB201719327D0 (en) New compounds and uses
GB201719233D0 (en) New compounds and uses
GB201714743D0 (en) New compounds and uses

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)